Circulating Endothelial Cells for Evaluation of Tumor Response in Non-Small Cell lung cancer patients receiving first-line chemotherapy
Background Circulating endothelial cells (CECs) reflect the neovascularization in the tumor mass. We therefore investigated the potential role of CEC kinetics after first-line chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. Methods Peripheral blood samples were obtained from 45...
Gespeichert in:
| Veröffentlicht in: | The International journal of biological markers 2015-10, Vol.30 (4), p.374-381 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 381 |
|---|---|
| container_issue | 4 |
| container_start_page | 374 |
| container_title | The International journal of biological markers |
| container_volume | 30 |
| creator | Najjar, Fadi Al-Massarani, Ghassan Banat, Israa Alammar, Moosheer |
| description | Background
Circulating endothelial cells (CECs) reflect the neovascularization in the tumor mass. We therefore investigated the potential role of CEC kinetics after first-line chemotherapy in advanced non-small cell lung cancer (NSCLC) patients.
Methods
Peripheral blood samples were obtained from 45 healthy subjects and 51 naïve patients with advanced NSCLC. Quantification of CD146+ CECs was performed using immunomagnetic separation (IMS).
Results
Pretreatment and posttreatment CEC levels in NSCLC patients were significantly higher than in healthy subjects (p |
| doi_str_mv | 10.5301/jbm.5000154 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_AFRWT</sourceid><recordid>TN_cdi_proquest_miscellaneous_1737479473</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.5301_jbm.5000154</sage_id><sourcerecordid>1737479473</sourcerecordid><originalsourceid>FETCH-LOGICAL-c317t-8246706e9b7840d3dadd4feb1e4d3ff15a83032e48a793a525d9e4c67ac3d8213</originalsourceid><addsrcrecordid>eNptkEtLxDAUhYMoOj5W7iVLQapJkzbtUobxAaKg47pkklvNkCY1aYX5Bf5tM8yoG1cXLt85596D0CkllwUj9Gq56C4LQggt-A6aUJHzrCSk2kUTwmqWlbQoDtBhjEtCckpEuY8O8pKSmpVsgr6mJqjRysG4Nzxz2g_vYI20eArWRtz6gGef0o4J8A77Fs_HLu2eIfbeRcDG4UfvspdO2o0G2zE5KekUBNwnGbgh4gAKzOc6ozUhDpk1DrB6h26dF2S_OkZ7rbQRTrbzCL3ezObTu-zh6fZ-ev2QKUbFkFU5LwUpoV6IihPNtNSat7CgwDVrW1rIihGWA6-kqJks8kLXwFUppGK6yik7Qucb3z74jxHi0HQmqnS3dODH2FDBBBc1FyyhFxtUBR9jgLbpg-lkWDWUNOvmm9R8s20-0Wdb43HRgf5lf6r-S47yDZqlH4NLj_7r9Q3A-o1o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1737479473</pqid></control><display><type>article</type><title>Circulating Endothelial Cells for Evaluation of Tumor Response in Non-Small Cell lung cancer patients receiving first-line chemotherapy</title><source>Sage Journals GOLD Open Access 2024</source><creator>Najjar, Fadi ; Al-Massarani, Ghassan ; Banat, Israa ; Alammar, Moosheer</creator><creatorcontrib>Najjar, Fadi ; Al-Massarani, Ghassan ; Banat, Israa ; Alammar, Moosheer</creatorcontrib><description>Background
Circulating endothelial cells (CECs) reflect the neovascularization in the tumor mass. We therefore investigated the potential role of CEC kinetics after first-line chemotherapy in advanced non-small cell lung cancer (NSCLC) patients.
Methods
Peripheral blood samples were obtained from 45 healthy subjects and 51 naïve patients with advanced NSCLC. Quantification of CD146+ CECs was performed using immunomagnetic separation (IMS).
Results
Pretreatment and posttreatment CEC levels in NSCLC patients were significantly higher than in healthy subjects (p<0.0001). An objective response was achieved after chemotherapy with partial response (PR) or stable disease (SD) in 26 patients, whereas the remaining 25 patients had progressive disease (PD). Baseline CEC levels were significantly higher in PR/SD patients than in PD patients (p = 0.039). After chemotherapy, CEC count significantly decreased in PR/SD patients (p = 0.014) and increased in patients with PD (p = 0.019). Moreover, there was a significant difference in the percentage change of CEC counts between the 2 groups (p = 0.0016). No significant difference in the median progression-free survival and overall survival (OS) was observed between patients with high baseline CEC counts and those with low baseline CEC levels. However, patients with high percentage change in CEC count had longer OS than those with low percentage change after chemotherapy (p = 0.05).
Conclusions
Changes in CEC counts after chemotherapy reflect tumor response in advanced NSCLC patients. Moreover, high percentage changes in CEC counts after chemotherapy may predict longer OS in advanced NSCLC. High baseline CEC levels might be an indicator of tumor response in advanced NSCLC patients after first-line chemotherapy.</description><identifier>ISSN: 0393-6155</identifier><identifier>EISSN: 1724-6008</identifier><identifier>DOI: 10.5301/jbm.5000154</identifier><identifier>PMID: 26109363</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject><![CDATA[Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Carboplatin - administration & dosage ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - pathology ; Case-Control Studies ; Cisplatin - administration & dosage ; Deoxycytidine - administration & dosage ; Deoxycytidine - analogs & derivatives ; Disease-Free Survival ; Endothelial Cells - pathology ; Etoposide - administration & dosage ; Female ; Humans ; Kaplan-Meier Estimate ; Lung Neoplasms - drug therapy ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Male ; Middle Aged ; Neoplastic Cells, Circulating - pathology ; Neovascularization, Pathologic - drug therapy ; Neovascularization, Pathologic - mortality ; Neovascularization, Pathologic - pathology ; Paclitaxel - administration & dosage ; Prospective Studies ; Taxoids - administration & dosage ; Treatment Outcome ; Vinblastine - administration & dosage ; Vinblastine - analogs & derivatives]]></subject><ispartof>The International journal of biological markers, 2015-10, Vol.30 (4), p.374-381</ispartof><rights>2015 SAGE Publications</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c317t-8246706e9b7840d3dadd4feb1e4d3ff15a83032e48a793a525d9e4c67ac3d8213</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.5301/jbm.5000154$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.5301/jbm.5000154$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21966,27853,27924,27925,44945,45333</link.rule.ids><linktorsrc>$$Uhttps://journals.sagepub.com/doi/full/10.5301/jbm.5000154?utm_source=summon&utm_medium=discovery-provider$$EView_record_in_SAGE_Publications$$FView_record_in_$$GSAGE_Publications</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26109363$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Najjar, Fadi</creatorcontrib><creatorcontrib>Al-Massarani, Ghassan</creatorcontrib><creatorcontrib>Banat, Israa</creatorcontrib><creatorcontrib>Alammar, Moosheer</creatorcontrib><title>Circulating Endothelial Cells for Evaluation of Tumor Response in Non-Small Cell lung cancer patients receiving first-line chemotherapy</title><title>The International journal of biological markers</title><addtitle>Int J Biol Markers</addtitle><description>Background
Circulating endothelial cells (CECs) reflect the neovascularization in the tumor mass. We therefore investigated the potential role of CEC kinetics after first-line chemotherapy in advanced non-small cell lung cancer (NSCLC) patients.
Methods
Peripheral blood samples were obtained from 45 healthy subjects and 51 naïve patients with advanced NSCLC. Quantification of CD146+ CECs was performed using immunomagnetic separation (IMS).
Results
Pretreatment and posttreatment CEC levels in NSCLC patients were significantly higher than in healthy subjects (p<0.0001). An objective response was achieved after chemotherapy with partial response (PR) or stable disease (SD) in 26 patients, whereas the remaining 25 patients had progressive disease (PD). Baseline CEC levels were significantly higher in PR/SD patients than in PD patients (p = 0.039). After chemotherapy, CEC count significantly decreased in PR/SD patients (p = 0.014) and increased in patients with PD (p = 0.019). Moreover, there was a significant difference in the percentage change of CEC counts between the 2 groups (p = 0.0016). No significant difference in the median progression-free survival and overall survival (OS) was observed between patients with high baseline CEC counts and those with low baseline CEC levels. However, patients with high percentage change in CEC count had longer OS than those with low percentage change after chemotherapy (p = 0.05).
Conclusions
Changes in CEC counts after chemotherapy reflect tumor response in advanced NSCLC patients. Moreover, high percentage changes in CEC counts after chemotherapy may predict longer OS in advanced NSCLC. High baseline CEC levels might be an indicator of tumor response in advanced NSCLC patients after first-line chemotherapy.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Carboplatin - administration & dosage</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Case-Control Studies</subject><subject>Cisplatin - administration & dosage</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Disease-Free Survival</subject><subject>Endothelial Cells - pathology</subject><subject>Etoposide - administration & dosage</subject><subject>Female</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplastic Cells, Circulating - pathology</subject><subject>Neovascularization, Pathologic - drug therapy</subject><subject>Neovascularization, Pathologic - mortality</subject><subject>Neovascularization, Pathologic - pathology</subject><subject>Paclitaxel - administration & dosage</subject><subject>Prospective Studies</subject><subject>Taxoids - administration & dosage</subject><subject>Treatment Outcome</subject><subject>Vinblastine - administration & dosage</subject><subject>Vinblastine - analogs & derivatives</subject><issn>0393-6155</issn><issn>1724-6008</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkEtLxDAUhYMoOj5W7iVLQapJkzbtUobxAaKg47pkklvNkCY1aYX5Bf5tM8yoG1cXLt85596D0CkllwUj9Gq56C4LQggt-A6aUJHzrCSk2kUTwmqWlbQoDtBhjEtCckpEuY8O8pKSmpVsgr6mJqjRysG4Nzxz2g_vYI20eArWRtz6gGef0o4J8A77Fs_HLu2eIfbeRcDG4UfvspdO2o0G2zE5KekUBNwnGbgh4gAKzOc6ozUhDpk1DrB6h26dF2S_OkZ7rbQRTrbzCL3ezObTu-zh6fZ-ev2QKUbFkFU5LwUpoV6IihPNtNSat7CgwDVrW1rIihGWA6-kqJks8kLXwFUppGK6yik7Qucb3z74jxHi0HQmqnS3dODH2FDBBBc1FyyhFxtUBR9jgLbpg-lkWDWUNOvmm9R8s20-0Wdb43HRgf5lf6r-S47yDZqlH4NLj_7r9Q3A-o1o</recordid><startdate>20151001</startdate><enddate>20151001</enddate><creator>Najjar, Fadi</creator><creator>Al-Massarani, Ghassan</creator><creator>Banat, Israa</creator><creator>Alammar, Moosheer</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20151001</creationdate><title>Circulating Endothelial Cells for Evaluation of Tumor Response in Non-Small Cell lung cancer patients receiving first-line chemotherapy</title><author>Najjar, Fadi ; Al-Massarani, Ghassan ; Banat, Israa ; Alammar, Moosheer</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c317t-8246706e9b7840d3dadd4feb1e4d3ff15a83032e48a793a525d9e4c67ac3d8213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Carboplatin - administration & dosage</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Case-Control Studies</topic><topic>Cisplatin - administration & dosage</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Disease-Free Survival</topic><topic>Endothelial Cells - pathology</topic><topic>Etoposide - administration & dosage</topic><topic>Female</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplastic Cells, Circulating - pathology</topic><topic>Neovascularization, Pathologic - drug therapy</topic><topic>Neovascularization, Pathologic - mortality</topic><topic>Neovascularization, Pathologic - pathology</topic><topic>Paclitaxel - administration & dosage</topic><topic>Prospective Studies</topic><topic>Taxoids - administration & dosage</topic><topic>Treatment Outcome</topic><topic>Vinblastine - administration & dosage</topic><topic>Vinblastine - analogs & derivatives</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Najjar, Fadi</creatorcontrib><creatorcontrib>Al-Massarani, Ghassan</creatorcontrib><creatorcontrib>Banat, Israa</creatorcontrib><creatorcontrib>Alammar, Moosheer</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The International journal of biological markers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Najjar, Fadi</au><au>Al-Massarani, Ghassan</au><au>Banat, Israa</au><au>Alammar, Moosheer</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circulating Endothelial Cells for Evaluation of Tumor Response in Non-Small Cell lung cancer patients receiving first-line chemotherapy</atitle><jtitle>The International journal of biological markers</jtitle><addtitle>Int J Biol Markers</addtitle><date>2015-10-01</date><risdate>2015</risdate><volume>30</volume><issue>4</issue><spage>374</spage><epage>381</epage><pages>374-381</pages><issn>0393-6155</issn><eissn>1724-6008</eissn><abstract>Background
Circulating endothelial cells (CECs) reflect the neovascularization in the tumor mass. We therefore investigated the potential role of CEC kinetics after first-line chemotherapy in advanced non-small cell lung cancer (NSCLC) patients.
Methods
Peripheral blood samples were obtained from 45 healthy subjects and 51 naïve patients with advanced NSCLC. Quantification of CD146+ CECs was performed using immunomagnetic separation (IMS).
Results
Pretreatment and posttreatment CEC levels in NSCLC patients were significantly higher than in healthy subjects (p<0.0001). An objective response was achieved after chemotherapy with partial response (PR) or stable disease (SD) in 26 patients, whereas the remaining 25 patients had progressive disease (PD). Baseline CEC levels were significantly higher in PR/SD patients than in PD patients (p = 0.039). After chemotherapy, CEC count significantly decreased in PR/SD patients (p = 0.014) and increased in patients with PD (p = 0.019). Moreover, there was a significant difference in the percentage change of CEC counts between the 2 groups (p = 0.0016). No significant difference in the median progression-free survival and overall survival (OS) was observed between patients with high baseline CEC counts and those with low baseline CEC levels. However, patients with high percentage change in CEC count had longer OS than those with low percentage change after chemotherapy (p = 0.05).
Conclusions
Changes in CEC counts after chemotherapy reflect tumor response in advanced NSCLC patients. Moreover, high percentage changes in CEC counts after chemotherapy may predict longer OS in advanced NSCLC. High baseline CEC levels might be an indicator of tumor response in advanced NSCLC patients after first-line chemotherapy.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>26109363</pmid><doi>10.5301/jbm.5000154</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 0393-6155 |
| ispartof | The International journal of biological markers, 2015-10, Vol.30 (4), p.374-381 |
| issn | 0393-6155 1724-6008 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1737479473 |
| source | Sage Journals GOLD Open Access 2024 |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carboplatin - administration & dosage Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Case-Control Studies Cisplatin - administration & dosage Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Disease-Free Survival Endothelial Cells - pathology Etoposide - administration & dosage Female Humans Kaplan-Meier Estimate Lung Neoplasms - drug therapy Lung Neoplasms - mortality Lung Neoplasms - pathology Male Middle Aged Neoplastic Cells, Circulating - pathology Neovascularization, Pathologic - drug therapy Neovascularization, Pathologic - mortality Neovascularization, Pathologic - pathology Paclitaxel - administration & dosage Prospective Studies Taxoids - administration & dosage Treatment Outcome Vinblastine - administration & dosage Vinblastine - analogs & derivatives |
| title | Circulating Endothelial Cells for Evaluation of Tumor Response in Non-Small Cell lung cancer patients receiving first-line chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T23%3A52%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_AFRWT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circulating%20Endothelial%20Cells%20for%20Evaluation%20of%20Tumor%20Response%20in%20Non-Small%20Cell%20lung%20cancer%20patients%20receiving%20first-line%20chemotherapy&rft.jtitle=The%20International%20journal%20of%20biological%20markers&rft.au=Najjar,%20Fadi&rft.date=2015-10-01&rft.volume=30&rft.issue=4&rft.spage=374&rft.epage=381&rft.pages=374-381&rft.issn=0393-6155&rft.eissn=1724-6008&rft_id=info:doi/10.5301/jbm.5000154&rft_dat=%3Cproquest_AFRWT%3E1737479473%3C/proquest_AFRWT%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1737479473&rft_id=info:pmid/26109363&rft_sage_id=10.5301_jbm.5000154&rfr_iscdi=true |